These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20166509)

  • 41. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 42. The FDA: is it protecting the public with one hand tied behind its back?
    Shedlin RS
    Law Med Health Care; 1992; 20(3):253-7. PubMed ID: 1434771
    [No Abstract]   [Full Text] [Related]  

  • 43. Pain, inflammation and a nodule after IV medication.
    Craig A
    Adv Nurse Pract; 2005 Jul; 13(7):21-2. PubMed ID: 16035546
    [No Abstract]   [Full Text] [Related]  

  • 44. Congress may force drug firms to reveal clinical trial data.
    Check E
    Nature; 2004 Sep; 431(7006):232. PubMed ID: 15371992
    [No Abstract]   [Full Text] [Related]  

  • 45. Legal Challenges to State Drug Pricing Laws.
    Lee TT; Kesselheim AS; Kapczynski A
    JAMA; 2018 Mar; 319(9):865-866. PubMed ID: 29435585
    [No Abstract]   [Full Text] [Related]  

  • 46. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 47. US Congress to consider limits on DTCA.
    Guthrie P
    CMAJ; 2007 May; 176(10):1404. PubMed ID: 17485685
    [No Abstract]   [Full Text] [Related]  

  • 48. Relative efficacy of the proposed Space Shuttle antimotion sickness medications.
    Hordinsky JR; Schwartz E; Beier J; Martin J; Aust G
    Acta Astronaut; 1982; 9(6-7):375-83. PubMed ID: 11541691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 50. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 51. The policy outlook from the Hill.
    Vastag B
    Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381
    [No Abstract]   [Full Text] [Related]  

  • 52. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 53. [Congenital gangrene of the right upper limb].
    Sanjuán Rodríguez S; Morán Penco JM; Chávez Loroño D; Torres Sánchez-Pallasar C; Santamaría Ossorio I
    An Esp Pediatr; 1982 Aug; 17(2):140-2. PubMed ID: 6293355
    [No Abstract]   [Full Text] [Related]  

  • 54. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA issues draft 'concept paper' on drug company funding of CME.
    Skolnick A
    JAMA; 1991 Dec; 266(21):2947-8. PubMed ID: 1820457
    [No Abstract]   [Full Text] [Related]  

  • 56. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 57. Bush's 'parting gifts'.
    Farley SJ
    Nat Clin Pract Urol; 2009 Mar; 6(3):117. PubMed ID: 19265854
    [No Abstract]   [Full Text] [Related]  

  • 58. State regulation of Canadian pharmacies: a prescription to violate the supremacy clause.
    Kleiman ME
    Am J Law Med; 2006; 32(2-3):219-46. PubMed ID: 16927611
    [No Abstract]   [Full Text] [Related]  

  • 59. No more than necessary: safety and efficacy of low-dose promethazine.
    Moser JD; Caldwell JB; Rhule FJ
    Ann Pharmacother; 2006 Jan; 40(1):45-8. PubMed ID: 16352779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.